Carisma Competitors
| CARM Stock | 0.05 0.01 17.95% |
Carisma Therapeutics vs Aspire BioPharma Correlation
Modest diversification
The correlation between Carisma Therapeutics and ASBP is 0.2 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Carisma Therapeutics and ASBP in the same portfolio, assuming nothing else is changed.
Moving together with Carisma Stock
Moving against Carisma Stock
| 0.58 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.51 | ENGN | enGene Holdings Common | PairCorr |
| 0.46 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.44 | DSGN | Design Therapeutics | PairCorr |
| 0.37 | KYTX | Kyverna Therapeutics | PairCorr |
Carisma Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Carisma Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Carisma and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Carisma Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Carisma Stock performing well and Carisma Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Carisma Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| JSPR | 4.23 | (0.56) | 0.00 | (1.12) | 0.00 | 7.73 | 31.75 | |||
| ONCO | 4.89 | (1.27) | 0.00 | 6.73 | 0.00 | 9.09 | 36.81 | |||
| ENVB | 6.90 | (0.97) | 0.00 | (0.53) | 0.00 | 11.13 | 121.83 | |||
| SPRC | 4.36 | (2.33) | 0.00 | (1.48) | 0.00 | 5.00 | 30.69 | |||
| SLXN | 4.34 | (1.02) | 0.00 | (0.34) | 0.00 | 15.09 | 37.24 | |||
| SLRX | 6.68 | (2.16) | 0.00 | (0.67) | 0.00 | 16.00 | 61.05 | |||
| REVB | 4.09 | (1.63) | 0.00 | (0.60) | 0.00 | 6.84 | 35.57 | |||
| CDT | 5.20 | (1.18) | 0.00 | (0.34) | 0.00 | 12.43 | 40.12 | |||
| INDP | 6.34 | (0.77) | 0.00 | (0.13) | 0.00 | 16.13 | 51.64 | |||
| ASBP | 8.61 | (2.59) | 0.00 | 4.18 | 0.00 | 19.52 | 66.08 |
Cross Equities Net Income Analysis
Compare Carisma Therapeutics and related stocks such as Jasper Therapeutics, Onconetix, and Enveric Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JSPR | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (31.7 M) | (30.6 M) | (37.7 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
| ONCO | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (1.6 M) | (3.4 M) | (13.4 M) | (37.4 M) | (58.7 M) | (52.8 M) | (50.2 M) |
| ENVB | (1.2 M) | (33.4 K) | (24.6 K) | (161) | (33.6 K) | (1.9 M) | (2.8 M) | (9.1 M) | (16.9 M) | (5.6 M) | (6.9 M) | (49 M) | (18.5 M) | (17.3 K) | (9.6 M) | (8.6 M) | (8.2 M) |
| SPRC | (1.7 M) | (3.7 M) | (3.5 M) | 59.4 K | (1.9 M) | (2.5 M) | (2 M) | (6.2 M) | (8.5 M) | (5.4 M) | (3.5 M) | (5.8 M) | (2.6 M) | (5.1 M) | (6.3 M) | (5.7 M) | (5.9 M) |
| SLXN | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (755.2 K) | (3.2 M) | (4.9 M) | (16.4 M) | (14.8 M) | (14.1 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| CDT | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (4.9 M) | (535 K) | (17.8 M) | (16 M) | (15.2 M) |
| INDP | (5.4 M) | (7.6 M) | (5.2 M) | (5.1 M) | (5.7 M) | (7.2 M) | (13.4 M) | (28.9 M) | (43.5 M) | (47.6 M) | (3.6 M) | (7.7 M) | (14.3 M) | (15.4 M) | (15 M) | (13.5 M) | (14.2 M) |
| ASBP | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | 3.3 M | 4.5 M | (12.5 M) | (11.3 M) | (10.7 M) |
Carisma Therapeutics and related stocks such as Jasper Therapeutics, Onconetix, and Enveric Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Carisma Therapeutics financial statement analysis. It represents the amount of money remaining after all of Carisma Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Carisma Therapeutics Competitive Analysis
The better you understand Carisma Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Carisma Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Carisma Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Carisma Therapeutics Competition Performance Charts
Five steps to successful analysis of Carisma Therapeutics Competition
Carisma Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Carisma Therapeutics in relation to its competition. Carisma Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Carisma Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Carisma Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Carisma Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Carisma Therapeutics position
In addition to having Carisma Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Junk Bonds Funds Thematic Idea Now
Junk Bonds Funds
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Carisma Therapeutics Correlation with its peers. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Biotechnology sector continue expanding? Could Carisma diversify its offerings? Factors like these will boost the valuation of Carisma Therapeutics. Projected growth potential of Carisma fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Carisma Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.19 | Revenue Per Share | Quarterly Revenue Growth 12.368 | Return On Assets | Return On Equity |
Understanding Carisma Therapeutics requires distinguishing between market price and book value, where the latter reflects Carisma's accounting equity. The concept of intrinsic value - what Carisma Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Carisma Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Carisma Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Carisma Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Carisma Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.